Minnesota sues Insys Therapeutics for illegally marketing opioid drug
Category: #health  By Dhananjay Punekar  Date: 2018-06-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Minnesota sues Insys Therapeutics for illegally marketing opioid drug

Minnesota has filed a litigation against Insys Therapeutics Inc., a U.S. based specialty pharma firm, for having illegally advertised a strong fentanyl-based pain killing drug. The legal suit filed by the Attorney General of Minnesota includes accusations against the firm for promoting the unapproved use of opioid medicine on the grounds of lessening the pain in cancer patients

Last month, the ex-sales representative of Insys, Natalie Perhacs, had been proved guilty for bribing two physicians in Alabama for prescribing the medicine. Apparently, she was sentenced to home confinement for five years by the U.S. District court in the opioid case.

In 2016, six former officials of Insys were charged in the scheme for promoting its painkilling drug Subsys, (which has incidentally received U.S. FDA approval for its use as a painkiller in cancer subjects) by offering kickbacks to doctors for prescribing the drug.  Yesterday, a former salesperson of the specialty pharma company, Michelle Breitenbach, had pleaded guilty before a law court in New Jersey. She was found to have bribed healthcare service providers for recommending Subsys to the patients and was sentenced to five years in prison.

The lawsuit registered against Insys in the District court of Hennepin County of Minnesota claimed that the pharma firm is encouraging physicians to recommend Subsys to patients diagnosed for medical conditions other than cancer, that too, at unapproved dosages. The litigation also alleges Insys of giving the nearly USD 43,000 to doctors in Minnesota as “speaker fees” for prescribing Subsys to their patients.

Earlier, the Minnesota Board of Pharmacy, which had filed a litigation against Insys in Swanson, sought civil penalties against the firm through administrative action. However, Insys has announced that it is going to hold settlement discussions with the U.S. Justice department and is ready to pay compensation of nearly USD 150 million to resolve the charges.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...